Federal Drug Administration panel recommends approval of Cancidas, Merck's investigational antifungal drug.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D017277:Drug Approval; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy* / Q000821:virology*; D010455:Peptides; D010456:Peptides, Cyclic; D014481:United States
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin